UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006005 |
|---|---|
| Receipt number | R000007106 |
| Scientific Title | The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis |
| Date of disclosure of the study information | 2011/07/20 |
| Last modified on | 2020/01/24 11:15:40 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis
Acronym
The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis
Scientific Title
The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis
Scientific Title:Acronym
The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis
Region
| Japan |
Condition
Condition
Type 2 Diabetes Mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the effects of olmesartan medoxomil on pulse wave velocity (baPWV, CAVI) in type2 diabetes mellitus
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
To investigate the effects of olmesartan medoxomil on pulse wave velocity (baPWV, CAVI) in type2 diabetes mellitus
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Duration24 weeks
Type 2 Diabetes Mellitus
Drug therapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Patients who have systolic blood pressure 130mmHg and/or diastolic blood pressure in type 2 diabetes mellitus
Key exclusion criteria
patient who has the impairment of renal
function (Cr >2mg/dl)
patient who has malabsorption syndrome, the impairment of cerebral blood flow or epilepsy
patient who has hyperkalemia
patient who has severe cardiac, hepatic or pancreatic disorder
patient who has pregnant, nurses a baby or may get pregnant
patient who is unsuitable for this study (judged by a doctor)
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | Michio |
| Middle name | |
| Last name | Otsuki |
Organization
Osaka University Graduate school of Medicine
Division name
Department of Metabolic Medicine
Zip code
565-0871
Address
2-2 Yamada-oka, Suita, Osaka, Japan
TEL
06-6879-3732
otsuki@endmet.med.osaka-u.ac.jp
Public contact
Name of contact person
| 1st name | Michio |
| Middle name | |
| Last name | Otsuki |
Organization
Osaka University Graduate School of Medicine
Division name
Department of Metabolic Medicine
Zip code
565-0871
Address
2-2 Yamada-oka, Suita, Osaka, Japan
TEL
06-6879-3732
Homepage URL
otsuki@endmet.med.osaka-u.ac.jp
Sponsor or person
Institute
Department of Metabolic Medicine
Osaka University Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Department of Metabolic Medicine
Osaka University Graduate School of Medicine
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka University Clinical Research Review Committee
Address
2-15 Yamada-oka, Suita, Osaka, Japan
Tel
06-6879-5682
rinri@hp-crc.med.osaka-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 07 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 02 | Month | 10 | Day |
Date of IRB
| 2011 | Year | 02 | Month | 01 | Day |
Anticipated trial start date
| 2011 | Year | 02 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
| 2014 | Year | 12 | Month | 31 | Day |
Date trial data considered complete
| 2014 | Year | 12 | Month | 31 | Day |
Date analysis concluded
| 2016 | Year | 12 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2011 | Year | 07 | Month | 19 | Day |
Last modified on
| 2020 | Year | 01 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007106
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
